We know that prostate cancer is a heterogeneous disease, but most of our treatments are not based on the different molecular stratification exhibited by the disease. One of the differences we do recognize in the cancer is that some of the tumors have genetic DNA-repair defects. There has been evidence that in those cancers exhibiting [...]
The drugs called PARP inhibitors have been increasing discussed in the world of prostate cancer. There is every good reason to believe that we will continue to hear more about them and for certain select men with prostate cancer they will probably become a part of their treatment. In a recent paper published in the [...]
According to research published today in the British Journal of Cancer, routine testing for a faulty BRCA2 gene (Kote-Jarai Z et al, BRCA2 is a gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients British Journal of Cancer (2011) doi:10.1038/bjc.2011.383) in men under 65 years with prostate cancer could [...]
